Fenofibric acid (BioDeep_00000270929)

   

Chemicals and Drugs


代谢物信息卡片


2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propionic acid

化学式: C17H15ClO4 (318.065882)
中文名称: 非诺贝特酸
谱图信息: 最多检出来源 Viridiplantae(plant) 16.67%

分子结构信息

SMILES: c1cc(C(=O)c2ccc(cc2)OC(C(=O)O)(C)C)ccc1Cl
InChI: InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

描述信息

A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent
CONFIDENCE standard compound; EAWAG_UCHEM_ID 337
CONFIDENCE standard compound; INTERNAL_ID 2056
Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

同义名列表

3 个代谢物同义名

Fenofibric acid; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propionic acid; FNF acid



数据库引用编号

42 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of medicinal chemistry. 2020 05; 63(10):5031-5073. doi: 10.1021/acs.jmedchem.9b01701. [PMID: 31930920]
  • Hua Ling, John T Luoma, Daniel Hilleman. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiology research. 2013 Apr; 4(2):47-55. doi: 10.4021/cr270w. [PMID: 28352420]
  • Li Ma, Christie M Ballantyne, John W Belmont, Alon Keinan, Ariel Brautbar. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of lipid research. 2012 Nov; 53(11):2425-8. doi: 10.1194/jlr.m028829. [PMID: 22896670]
  • Hisao Nemoto, Masaki Kamiya, Aki Nakamoto, Tsuyoshi Matsushita, Kosuke Matsumura, Hatsuhiko Hattori, Tomoyuki Kawamura, Chiaki Taoka, Shinji Abe, Keisuke Ishizawa, Licht Miyamoto, Koichiro Tsuchiya. Synthesis of highly water-soluble fibrate derivatives via BGLation. Bioorganic & medicinal chemistry letters. 2012 Oct; 22(20):6425-8. doi: 10.1016/j.bmcl.2012.08.057. [PMID: 22975299]
  • Minh-Hien Hoang, Yaoyao Jia, Hee-jin Jun, Ji-Hae Lee, Dong-Ho Lee, Bang-Yeon Hwang, Woo-Jin Kim, Hak-Ju Lee, Sung-Joon Lee. Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells. Bioorganic & medicinal chemistry letters. 2012 Jun; 22(12):4094-9. doi: 10.1016/j.bmcl.2012.04.071. [PMID: 22579484]
  • Theodosios D Filippatos. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovascular drugs and therapy. 2012 Jun; 26(3):245-55. doi: 10.1007/s10557-012-6394-0. [PMID: 22592524]
  • Guanxiong Wang, Jifen Guo, Fanhua Meng, Xiaomei Song, Bohua Zhong, Yimin Zhao. Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. Biomedical chromatography : BMC. 2012 Apr; 26(4):497-501. doi: 10.1002/bmc.1693. [PMID: 21882209]
  • Karthik Ananthasubramaniam, Robert Weiss, Bruce McNutt, Barbara Klauke, Kathleen Feaheny, Stan Bukofzer. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2012 Apr; 19(2):319-29. doi: 10.1007/s12350-011-9508-3. [PMID: 22259009]
  • Keith C Ferdinand, Michael H Davidson, Maureen T Kelly, Carolyn M Setze. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2012 Apr; 12(2):117-25. doi: 10.2165/11597940-000000000-00000. [PMID: 22263674]
  • Ariel Brautbar, Salim S Virani, John Belmont, Vijay Nambi, Peter H Jones, Christie M Ballantyne. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Journal of lipid research. 2012 Mar; 53(3):556-560. doi: 10.1194/jlr.m020404. [PMID: 22236405]
  • Paulino Antonio Alvarez, Jose Egozcue, Jihan Sleiman, Lucas Moretti, Guillermo Di Girolamo, Guillermo Alberto Keller. Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate. Current drug safety. 2012 Feb; 7(1):24-9. doi: 10.2174/157488612800492708. [PMID: 22663953]
  • Jeffrey G Shanes. A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough. Current atherosclerosis reports. 2012 Feb; 14(1):33-40. doi: 10.1007/s11883-011-0222-z. [PMID: 22109348]
  • Yaoyao Jia, Muhammad Javidul Haque Bhuiyan, Hee-Jin Jun, Ji Hae Lee, Minh Hien Hoang, Hak-Ju Lee, Nahyun Kim, Dongho Lee, Kwang Yeon Hwang, Bang Yeon Hwang, Dal-Woong Choi, Sung-Joon Lee. Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism. Bioorganic & medicinal chemistry letters. 2011 Oct; 21(19):5876-80. doi: 10.1016/j.bmcl.2011.07.095. [PMID: 21855333]
  • Christie M Ballantyne, Michael H Davidson, Carolyn M Setze, Maureen T Kelly. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu. Journal of clinical lipidology. 2011 Sep; 5(5):401-7. doi: 10.1016/j.jacl.2011.06.010. [PMID: 21981842]
  • Babasaheb P Bandgar, Rajendra J Sarangdhar, Fruthous Khan, Jeyamurugan Mookkan, Pranesha Shetty, Gajendra Singh. Synthesis and biological evaluation of orally active hypolipidemic agents. Journal of medicinal chemistry. 2011 Aug; 54(16):5915-26. doi: 10.1021/jm200704f. [PMID: 21770455]
  • Syed M Mohiuddin, Kamlesh M Thakker, Carolyn M Setze, Maureen T Kelly. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current medical research and opinion. 2011 May; 27(5):1067-78. doi: 10.1185/03007995.2011.569018. [PMID: 21438793]
  • Anne C Goldberg, Vera Bittner, Carl J Pepine, Maureen T Kelly, Kamlesh Thakker, Carolyn M Setze, Aditya Lele, Darryl J Sleep. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. The American journal of cardiology. 2011 Mar; 107(6):898-905. doi: 10.1016/j.amjcard.2010.11.009. [PMID: 21247520]
  • Lloyd R Whitfield, Anthony R Porcari, Christine Alvey, Robert Abel, William Bullen, Daniel Hartman. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. Journal of clinical pharmacology. 2011 Mar; 51(3):378-88. doi: 10.1177/0091270010366446. [PMID: 20413454]
  • Robert S Rosenson, Dawn M Carlson, Maureen T Kelly, Carolyn M Setze, Boaz Hirshberg, James C Stolzenbach, Laura A Williams. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovascular drugs and therapy. 2011 Feb; 25(1):47-57. doi: 10.1007/s10557-010-6273-5. [PMID: 21174145]
  • Christie M Ballantyne, Peter H Jones, Maureen T Kelly, Carolyn M Setze, Aditya Lele, Kamlesh M Thakker, James C Stolzenbach. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovascular drugs and therapy. 2011 Feb; 25(1):59-67. doi: 10.1007/s10557-011-6280-1. [PMID: 21416219]
  • Krzysztof Łabuzek, Łukasz Bułdak, Anna Duława-Bułdak, Anna Bielecka, Robert Krysiak, Andrzej Madej, Bogusław Okopień. Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacological reports : PR. 2011; 63(5):1124-36. doi: 10.1016/s1734-1140(11)70631-4. [PMID: 22180354]
  • Eli M Roth, Robert S Rosenson, Dawn M Carlson, Sandra M Fukumoto, Carolyn M Setze, James W Blasetto, Nardev S Khurmi, James C Stolzenbach, Laura A Williams. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovascular drugs and therapy. 2010 Dec; 24(5-6):421-8. doi: 10.1007/s10557-010-6266-4. [PMID: 20953684]
  • Chi Hyun Kim, Ravirala Ramu, Jin Hee Ahn, Myung Ae Bae, Young Sik Cho. Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes. Molecular and cellular biochemistry. 2010 Nov; 344(1-2):91-8. doi: 10.1007/s11010-010-0532-4. [PMID: 20614230]
  • Tânia Vieira Madureira, Juliana Cristina Barreiro, Maria João Rocha, Eduardo Rocha, Quezia Bezerra Cass, Maria Elizabeth Tiritan. Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal). The Science of the total environment. 2010 Oct; 408(22):5513-20. doi: 10.1016/j.scitotenv.2010.07.069. [PMID: 20732709]
  • Ryuichiro Murakami, Hisashi Murakami, Hiroki Kataoka, Xian Wu Cheng, Ryotaro Takahashi, Yasushi Numaguchi, Toyoaki Murohara, Kenji Okumura. Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes. Life sciences. 2010 Oct; 87(15-16):495-500. doi: 10.1016/j.lfs.2010.09.005. [PMID: 20849861]
  • Carl J Pepine, Terry A Jacobson, Dawn M Carlson, Maureen T Kelly, Carolyn M Setze, Alex Gold, James C Stolzenbach, Laura A Williams. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clinical cardiology. 2010 Oct; 33(10):609-619. doi: 10.1002/clc.20830. [PMID: 20960535]
  • Peter H Jones, Anne C Goldberg, Howard R Knapp, Maureen T Kelly, Carolyn M Setze, James C Stolzenbach, Darryl J Sleep. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. American heart journal. 2010 Oct; 160(4):759-66. doi: 10.1016/j.ahj.2010.06.045. [PMID: 20934572]
  • J Campbell, S M Mohiuddin. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs of today (Barcelona, Spain : 1998). 2010 Oct; 46(10):757-64. doi: 10.1358/dot.2010.46.10.1519652. [PMID: 21076712]
  • Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf, Haralampos J Milionis. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular health and risk management. 2010 Aug; 6(?):525-39. doi: 10.2147/vhrm.s5593. [PMID: 20730069]
  • Tong Zhu, Jean-Claude Ansquer, Maureen T Kelly, Darryl J Sleep, Rajendra S Pradhan. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. Journal of clinical pharmacology. 2010 Aug; 50(8):914-21. doi: 10.1177/0091270009354995. [PMID: 20145261]
  • Jannes Woudenberg, Krzysztof P Rembacz, Fiona A J van den Heuvel, Titia E Woudenberg-Vrenken, Manon Buist-Homan, Mariska Geuken, Mark Hoekstra, Leo E Deelman, Carlos Enrich, Rob H Henning, Han Moshage, Klaas Nico Faber. Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes. Hepatology (Baltimore, Md.). 2010 May; 51(5):1744-53. doi: 10.1002/hep.23460. [PMID: 20146263]
  • Szilard Voros, Parag H Joshi, Gustavo Vazquez, Gina Roth, Laura Murrieta, Sarah Rinehart, Zhen Qian, Joseph Miller. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study. Journal of cardiovascular computed tomography. 2010 May; 4(3):164-72. doi: 10.1016/j.jcct.2010.03.005. [PMID: 20413364]
  • Susan M Schima, Stephanie R Maciejewski, Daniel E Hilleman, Mark A Williams, Syed M Mohiuddin. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert opinion on pharmacotherapy. 2010 Apr; 11(5):731-8. doi: 10.1517/14656560903575639. [PMID: 20210682]
  • Laurian Vlase, Adina Popa, Dana Muntean, Sorin E Leucuta. Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. Arzneimittel-Forschung. 2010; 60(9):560-3. doi: 10.1055/s-0031-1296325. [PMID: 21117499]
  • Daijiro Uetake, Iwao Ohno, Kimiyoshi Ichida, Yuichiro Yamaguchi, Hajime Saikawa, Hitoshi Endou, Tatsuo Hosoya. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Internal medicine (Tokyo, Japan). 2010; 49(2):89-94. doi: 10.2169/internalmedicine.49.2597. [PMID: 20075570]
  • Peter H Jones, Kenneth Cusi, Michael H Davidson, Maureen T Kelly, Carolyn M Setze, Kamlesh Thakker, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2010; 10(2):73-84. doi: 10.2165/10061630-000000000-00000. [PMID: 20136164]
  • Ching-Feng Cheng, Hsi-Hsien Chen, Heng Lin. Role of PPARα and Its Agonist in Renal Diseases. PPAR research. 2010; 2010(?):345098. doi: 10.1155/2010/345098. [PMID: 21076544]
  • Roberto Rosal, Ismael Rodea-Palomares, Karina Boltes, Francisca Fernández-Piñas, Francisco Leganés, Soledad Gonzalo, Alice Petre. Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms. Environmental science and pollution research international. 2010 Jan; 17(1):135-44. doi: 10.1007/s11356-009-0137-1. [PMID: 19333638]
  • Mark S Kipnes, Eli M Roth, James M Rhyne, Carolyn M Setze, Aditya Lele, Maureen T Kelly, Darryl J Sleep, James C Stolzenbach. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clinical drug investigation. 2010; 30(1):51-61. doi: 10.2165/11319800-000000000-00000. [PMID: 19995098]
  • Joe D Strain, Debra K Farver, James R Clem. A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy. Clinical pharmacology : advances and applications. 2010; 2(?):95-104. doi: 10.2147/cpaa.s7375. [PMID: 22291492]
  • Roberto Rosal, Antonio Rodríguez, José Antonio Perdigón-Melón, Alice Petre, Eloy García-Calvo, María José Gómez, Ana Agüera, Amadeo R Fernández-Alba. Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. Water research. 2010 Jan; 44(2):578-88. doi: 10.1016/j.watres.2009.07.004. [PMID: 19628245]
  • Eli M Roth, James M McKenney, Maureen T Kelly, Carolyn M Setze, Dawn M Carlson, Alex Gold, James C Stolzenbach, Laura A Williams, Peter H Jones. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2010; 10(3):175-86. doi: 10.2165/11533430-000000000-00000. [PMID: 20524719]
  • Robert Krysiak, Krzysztof Labuzek, Bogusław Okopień. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacological reports : PR. 2009 Nov; 61(6):1134-45. doi: 10.1016/s1734-1140(09)70176-8. [PMID: 20081249]
  • Jelena Tojcic, Marie-Odile Benoit-Biancamano, Michael H Court, Robert J Straka, Patrick Caron, Chantal Guillemette. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2009 Nov; 37(11):2236-43. doi: 10.1124/dmd.109.029058. [PMID: 19661212]
  • Dasandi Bhavesh, Sanjay Shah. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. Biomedical chromatography : BMC. 2009 Sep; 23(9):922-8. doi: 10.1002/bmc.1203. [PMID: 19353730]
  • Terry A Jacobson. Myopathy with statin-fibrate combination therapy: clinical considerations. Nature reviews. Endocrinology. 2009 Sep; 5(9):507-18. doi: 10.1038/nrendo.2009.151. [PMID: 19636324]
  • Aiming Liu, Andrew D Patterson, Zongtao Yang, Xinying Zhang, Wei Liu, Fayang Qiu, He Sun, Kristopher W Krausz, Jeffrey R Idle, Frank J Gonzalez, Renke Dai. Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug metabolism and disposition: the biological fate of chemicals. 2009 Jun; 37(6):1157-63. doi: 10.1124/dmd.108.025817. [PMID: 19251819]
  • Peter H Jones, Michael H Davidson, Moti L Kashyap, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027. [PMID: 18996523]
  • S Pierno, G M Camerino, V Cippone, J-F Rolland, J-F Desaphy, A De Luca, A Liantonio, G Bianco, J D Kunic, A L George, D Conte Camerino. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression. British journal of pharmacology. 2009 Apr; 156(8):1206-15. doi: 10.1111/j.1476-5381.2008.00079.x. [PMID: 19220292]
  • Peter H Jones, Michael H Davidson, Anne C Goldberg, Carl J Pepine, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Aditya Lele, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of clinical lipidology. 2009 Apr; 3(2):125-37. doi: 10.1016/j.jacl.2009.02.007. [PMID: 21291802]
  • Anne C Goldberg, Harold E Bays, Christie M Ballantyne, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. The American journal of cardiology. 2009 Feb; 103(4):515-22. doi: 10.1016/j.amjcard.2008.10.025. [PMID: 19195513]
  • Apurva Chandalia, Holly J Clarke, L Edward Clemens, Bindu Pandey, Vic Vicena, Paul Lee, Brian E Lavan, Francine M Gregoire. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. PPAR research. 2009; 2009(?):706852. doi: 10.1155/2009/706852. [PMID: 19404482]
  • Tong Zhu, Walid M Awni, Balakrishna Hosmane, Maureen T Kelly, Darryl J Sleep, James C Stolzenbach, Katty Wan, Titus O Chira, Rajendra S Pradhan. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. Journal of clinical pharmacology. 2009 Jan; 49(1):63-71. doi: 10.1177/0091270008325671. [PMID: 18952910]
  • Syed M Mohiuddin, Carl J Pepine, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. American heart journal. 2009 Jan; 157(1):195-203. doi: 10.1016/j.ahj.2008.08.027. [PMID: 19081418]
  • Melissa Runge-Morris, Thomas A Kocarek. Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. PPAR research. 2009; 2009(?):728941. doi: 10.1155/2009/728941. [PMID: 19680455]
  • Lily P H Yang, Gillian M Keating. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2009; 9(6):401-9. doi: 10.2165/11203920-000000000-00000. [PMID: 19929038]
  • Harold E Bays, Peter H Jones, Syed M Mohiuddin, Maureen T Kelly, Hsiaoming Sun, Carolyn M Setze, Susan M Buttler, Darryl J Sleep, James C Stolzenbach. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of clinical lipidology. 2008 Dec; 2(6):426-35. doi: 10.1016/j.jacl.2008.10.001. [PMID: 21291776]
  • Theodosios Filippatos, Haralampos J Milionis. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert opinion on investigational drugs. 2008 Oct; 17(10):1599-614. doi: 10.1517/13543784.17.10.1599. [PMID: 18808320]
  • Petra Thulin, Ingalill Rafter, Kenneth Stockling, Celine Tomkiewicz, Ensio Norjavaara, Martine Aggerbeck, Heike Hellmold, Ewa Ehrenborg, Ulf Andersson, Ian Cotgreave, Björn Glinghammar. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicology and applied pharmacology. 2008 Aug; 231(1):1-9. doi: 10.1016/j.taap.2008.03.007. [PMID: 18455211]
  • B Mertens, B Cahay, R Klinkenberg, B Streel. An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. Journal of chromatography. A. 2008 May; 1189(1-2):493-502. doi: 10.1016/j.chroma.2008.01.060. [PMID: 18342321]
  • Masaki Tsunoda, Naoki Kobayashi, Tomohiro Ide, Mari Utsumi, Michiaki Nagasawa, Koji Murakami. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. American journal of physiology. Endocrinology and metabolism. 2008 May; 294(5):E833-40. doi: 10.1152/ajpendo.00627.2007. [PMID: 18212024]
  • Sanae Kourimate, Cédric Le May, Cédric Langhi, Anne Laure Jarnoux, Khadija Ouguerram, Yassine Zaïr, Patrick Nguyen, Michel Krempf, Bertrand Cariou, Philippe Costet. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. The Journal of biological chemistry. 2008 Apr; 283(15):9666-73. doi: 10.1074/jbc.m705831200. [PMID: 18245819]
  • Tetsuo Asaki, Tomiyoshi Aoki, Taisuke Hamamoto, Yukiteru Sugiyama, Shinji Ohmachi, Kenji Kuwabara, Kohji Murakami, Makoto Todo. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Bioorganic & medicinal chemistry. 2008 Jan; 16(2):981-94. doi: 10.1016/j.bmc.2007.10.007. [PMID: 17964792]
  • Koh-Ichi Nakamura, Ikuo Inoue, Seiichiro Takahashi, Tsugikazu Komoda, Shigehiro Katayama. Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems. PPAR research. 2008; 2008(?):348610. doi: 10.1155/2008/348610. [PMID: 18317514]
  • Peter H Jones, Harold E Bays, Michael H Davidson, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clinical drug investigation. 2008; 28(10):625-34. doi: 10.2165/00044011-200828100-00003. [PMID: 18783301]
  • Michel Farnier. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular health and risk management. 2008; 4(5):991-1000. doi: 10.2147/vhrm.s3390. [PMID: 19183747]
  • Theunis C Goosen, Jonathan N Bauman, John A Davis, Chongwoo Yu, Susan I Hurst, J Andrew Williams, Cho-Ming Loi. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug metabolism and disposition: the biological fate of chemicals. 2007 Aug; 35(8):1315-24. doi: 10.1124/dmd.107.015230. [PMID: 17470524]
  • Thomas J F Nieland, Jared T Shaw, Firoz A Jaipuri, Zoltan Maliga, Jay L Duffner, Angela N Koehler, Monty Krieger. Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Journal of lipid research. 2007 Aug; 48(8):1832-45. doi: 10.1194/jlr.m700209-jlr200. [PMID: 17533223]
  • Xiao-Yan Chu, Kelly Bleasby, Jocelyn Yabut, Xiaoxin Cai, Grace Hoyee Chan, Michael J Hafey, Shiyao Xu, Arthur J Bergman, Matthew P Braun, Dennis C Dean, Raymond Evers. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. The Journal of pharmacology and experimental therapeutics. 2007 May; 321(2):673-83. doi: 10.1124/jpet.106.116517. [PMID: 17314201]
  • Per Sauerberg, Grith S Olsen, Lone Jeppesen, John P Mogensen, Ingrid Pettersson, Claus B Jeppesen, Jens R Daugaard, Elisabeth D Galsgaard, Lars Ynddal, Jan Fleckner, Vladimira Panajotova, Zdenek Polivka, Pavel Pihera, Miroslav Havranek, Erik M Wulff. Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. Journal of medicinal chemistry. 2007 Apr; 50(7):1495-503. doi: 10.1021/jm061202u. [PMID: 17343371]
  • Robert J Straka, R Todd Burkhardt, James E Fisher. Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum. Therapeutic drug monitoring. 2007 Apr; 29(2):197-202. doi: 10.1097/ftd.0b013e318030860a. [PMID: 17417074]
  • Michael L Sierra, Véronique Beneton, Anne-Bénédict Boullay, Thierry Boyer, Andrew G Brewster, Frédéric Donche, Marie-Claire Forest, Marie-Hélène Fouchet, Françoise J Gellibert, Didier A Grillot, Millard H Lambert, Alain Laroze, Christelle Le Grumelec, Jean Michel Linget, Valerie G Montana, Van-Loc Nguyen, Edwige Nicodème, Vipul Patel, Annie Penfornis, Olivier Pineau, Danig Pohin, Florent Potvain, Géraldine Poulain, Cécile Bertho Ruault, Michael Saunders, Jérôme Toum, H Eric Xu, Robert X Xu, Pascal M Pianetti. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. Journal of medicinal chemistry. 2007 Feb; 50(4):685-95. doi: 10.1021/jm058056x. [PMID: 17243659]
  • M D Hernando, A Agüera, A R Fernández-Alba. LC-MS analysis and environmental risk of lipid regulators. Analytical and bioanalytical chemistry. 2007 Feb; 387(4):1269-85. doi: 10.1007/s00216-006-0781-y. [PMID: 17047939]
  • Chiyoko Kunishima, Ikuo Inoue, Toshihiro Oikawa, Hiromu Nakajima, Tsugikazu Komoda, Shigehiro Katayama. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR research. 2007; 2007(?):36092. doi: 10.1155/2007/36092. [PMID: 18274627]
  • Alan M Warshawsky, Charles A Alt, Joseph T Brozinick, Allen R Harkness, Eric D Hawkins, James R Henry, Donald P Matthews, Anne R Miller, Elizabeth A Misener, Chahrzad Montrose-Rafizadeh, Gary A Rhodes, Quanrong Shen, Jennifer A Vance, Uko E Udodong, Minmin Wang, Tony Y Zhang, Richard W Zink. Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands. Bioorganic & medicinal chemistry letters. 2006 Dec; 16(24):6328-33. doi: 10.1016/j.bmcl.2006.09.011. [PMID: 17005394]
  • Ya Xu, Li Lu, Clifford Greyson, Mona Rizeq, Karin Nunley, Beata Wyatt, Michael R Bristow, Carlin S Long, Gregory G Schwartz. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. American journal of physiology. Heart and circulatory physiology. 2006 May; 290(5):H1798-807. doi: 10.1152/ajpheart.00631.2005. [PMID: 16339839]
  • Linda E Gustavson, Sarah M Schweitzer, David A Burt, Ramanuj Achari, Matthew J Rieser, Timi Edeki, Titus Chira, H Daniel Yannicelli, Maureen T Kelly. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clinical therapeutics. 2006 Mar; 28(3):373-87. doi: 10.1016/j.clinthera.2006.03.009. [PMID: 16750452]
  • R Sauron, M Wilkins, V Jessent, A Dubois, C Maillot, A Weil. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. International journal of clinical pharmacology and therapeutics. 2006 Feb; 44(2):64-70. doi: 10.5414/cpp44064. [PMID: 16502765]
  • Hwi-Yeol Yun, Eun Joo Lee, Soo Youn Chung, Sun-Ok Choi, Hyung Kee Kim, Jun-Tack Kwon, Wonku Kang, Kwang-Il Kwon. The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule. Clinical pharmacokinetics. 2006; 45(4):425-32. doi: 10.2165/00003088-200645040-00007. [PMID: 16584288]
  • Konstantinos Tziomalos, Vasilios G Athyros. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. International journal of nanomedicine. 2006; 1(2):129-47. doi: 10.2147/nano.2006.1.2.129. [PMID: 17722529]
  • Keisuke Tachibana, Yumi Kobayashi, Toshiya Tanaka, Masayuki Tagami, Akira Sugiyama, Tatsuya Katayama, Chihiro Ueda, Daisuke Yamasaki, Kenji Ishimoto, Mikako Sumitomo, Yasutoshi Uchiyama, Takahide Kohro, Juro Sakai, Takao Hamakubo, Tatsuhiko Kodama, Takefumi Doi. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nuclear receptor. 2005 Oct; 3(?):3. doi: 10.1186/1478-1336-3-3. [PMID: 16197558]
  • F Djouadi, F Aubey, D Schlemmer, J P N Ruiter, R J A Wanders, A W Strauss, Jean Bastin. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Human molecular genetics. 2005 Sep; 14(18):2695-703. doi: 10.1093/hmg/ddi303. [PMID: 16115821]
  • Ravi Kumar Trivedi, Raja Reddy Kallem, Ramesh Mullangi, Nuggehally R Srinivas. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. Journal of pharmaceutical and biomedical analysis. 2005 Sep; 39(3-4):661-9. doi: 10.1016/j.jpba.2005.05.005. [PMID: 15970417]
  • Markus Neumeier, Johanna Weigert, Andreas Schäffler, Thomas Weiss, Stefan Kirchner, Sabine Laberer, Jürgen Schölmerich, Christa Buechler. Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochemical and biophysical research communications. 2005 Sep; 334(3):924-9. doi: 10.1016/j.bbrc.2005.06.187. [PMID: 16023994]
  • M Yamazaki, B Li, S W Louie, N T Pudvah, R Stocco, W Wong, M Abramovitz, A Demartis, R Laufer, J H Hochman, T Prueksaritanont, J H Lin. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica; the fate of foreign compounds in biological systems. 2005 Jul; 35(7):737-53. doi: 10.1080/00498250500136676. [PMID: 16316932]
  • Reijiro Arakawa, Norimasa Tamehiro, Tomoko Nishimaki-Mogami, Kazumitsu Ueda, Shinji Yokoyama. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arteriosclerosis, thrombosis, and vascular biology. 2005 Jun; 25(6):1193-7. doi: 10.1161/01.atv.0000163844.07815.c4. [PMID: 15790930]
  • Pratik V Devasthale, Sean Chen, Yoon Jeon, Fucheng Qu, Chunning Shao, Wei Wang, Hao Zhang, Michael Cap, Dennis Farrelly, Rajasree Golla, Gary Grover, Thomas Harrity, Zhengping Ma, Lisa Moore, Jimmy Ren, Ramakrishna Seethala, Lin Cheng, Paul Sleph, Wei Sun, Aaron Tieman, John R Wetterau, Arthur Doweyko, Gamini Chandrasena, Shu Y Chang, W Griffith Humphreys, Vito G Sasseville, Scott A Biller, Denis E Ryono, Fred Selan, Narayanan Hariharan, Peter T W Cheng. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. Journal of medicinal chemistry. 2005 Mar; 48(6):2248-50. doi: 10.1021/jm0496436. [PMID: 15771468]
  • Sébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, Tania Roskams, Yang Cheng, Laurent Dubuquoy, Philippe Podevin, Filoména Conti, Valérie Canva, David Philippe, Luc Gambiez, Philippe Mathurin, Jean-Claude Paris, Kristina Schoonjans, Yvon Calmus, Stanislas Pol, Johan Auwerx, Pierre Desreumaux. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005 Feb; 128(2):334-42. doi: 10.1053/j.gastro.2004.11.016. [PMID: 15685545]
  • José A Martín, Dawn A Brooks, Lourdes Prieto, Rosario González, Alicia Torrado, Isabel Rojo, Beatriz López de Uralde, Carlos Lamas, Rafael Ferritto, María Dolores Martín-Ortega, Javier Agejas, Francisco Parra, John R Rizzo, Gary A Rhodes, Roger L Robey, Charles A Alt, Samuel R Wendel, Tony Y Zhang, Anne Reifel-Miller, Chahrzad Montrose-Rafizadeh, Joseph T Brozinick, Eric Hawkins, Elizabeth A Misener, Daniel A Briere, Robert Ardecky, James D Fraser, Alan M Warshawsky. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Bioorganic & medicinal chemistry letters. 2005 Jan; 15(1):51-5. doi: 10.1016/j.bmcl.2004.10.042. [PMID: 15582409]
  • James M Backes, Cheryl A Gibson, Patricia A Howard. Optimal lipid modification: the rationale for combination therapy. Vascular health and risk management. 2005; 1(4):317-31. doi: 10.2147/vhrm.2005.1.4.317. [PMID: 17315604]
  • Pol-Henri Guivarc'h, Michael G Vachon, Diana Fordyce. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clinical therapeutics. 2004 Sep; 26(9):1456-69. doi: 10.1016/j.clinthera.2004.09.015. [PMID: 15531008]
  • Arthur J Bergman, Gail Murphy, Joanne Burke, Jamie J Zhao, Robert Valesky, Lida Liu, Kenneth C Lasseter, Weili He, Thomayant Prueksaritanont, Yue Qiu, Alan Hartford, Jose M Vega, John F Paolini. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. Journal of clinical pharmacology. 2004 Sep; 44(9):1054-62. doi: 10.1177/0091270004268044. [PMID: 15317833]
  • Kenji Kuwabara, Kohji Murakami, Makoto Todo, Tomiyoshi Aoki, Tetsuo Asaki, Masatoshi Murai, Junichi Yano. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. The Journal of pharmacology and experimental therapeutics. 2004 Jun; 309(3):970-7. doi: 10.1124/jpet.103.064659. [PMID: 14982965]
  • Zak K Shihabi. Fenofibrate and fenofibric acid analysis by capillary electrophoresis. Electrophoresis. 2004 Jun; 25(10-11):1648-51. doi: 10.1002/elps.200305849. [PMID: 15188253]
  • Yves Rival, Nathalie Benéteau, Violaine Chapuis, Thierry Taillandier, Fabrice Lestienne, Elisabeth Dupont-Passelaigue, Jean-François Patoiseau, Francis C Colpaert, Didier Junquéro. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA and cell biology. 2004 May; 23(5):283-92. doi: 10.1089/104454904323090912. [PMID: 15169608]
  • Manuela Ehrhardt, Heike Lindenmaier, Juergen Burhenne, Walter Emil Haefeli, Johanna Weiss. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004 Jan; 67(2):285-92. doi: 10.1016/j.bcp.2003.09.008. [PMID: 14698041]
  • Michael R Jones, Brian A Baker, Philip Mathew. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clinical pharmacokinetics. 2004; 43(13):943-50. doi: 10.2165/00003088-200443130-00006. [PMID: 15509187]
  • Olivier Barbier, Daniel Duran-Sandoval, Inés Pineda-Torra, Vladimir Kosykh, Jean-Charles Fruchart, Bart Staels. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. The Journal of biological chemistry. 2003 Aug; 278(35):32852-60. doi: 10.1074/jbc.m305361200. [PMID: 12810707]
  • Kazuo Sonoki, Masanori Iwase, Kenzo Iino, Kojiro Ichikawa, Mototaka Yoshinari, Shigehiro Ohdo, Shun Higuchi, Mitsuo Iida. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. European journal of pharmacology. 2003 Aug; 475(1-3):139-47. doi: 10.1016/s0014-2999(03)02109-5. [PMID: 12954370]